An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery

•Caucasian hip or knee replacement patients with moderate renal impairment received dabigatran etexilate 150mg once daily•Four of 100 patients had major bleeds and none had venous thromboembolism•Results support this dabigatran dose in this patient population•Results suggest that, if needed, the diluted thrombin time can be used to quantify dabigatran concentrations